Your browser doesn't support javascript.
loading
Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum ß-lactamases in the SMART study in Spain (2002-2010).
Cantón, Rafael; Loza, Elena; Aznar, Javier; Calvo, Jorge; Cercenado, Emilia; Cisterna, Ramón; Romo, Fernando González; Hontangas, José Luis López; Calvo, Carmen Rubio; Barrenechea, Ana Isabel Suárez; Tubau, Fe; Weber, Irene; Yuste, Patricia; Cavanillas, Rafael.
Afiliação
  • Cantón R; Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Km 9.1, 28034 Madrid, Spain. rcanton.hrc@salud.madrid.org
Rev Esp Quimioter ; 24(4): 223-32, 2011 Dec.
Article em En | MEDLINE | ID: mdl-22173194
ABSTRACT

INTRODUCTION:

The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study records the antimicrobial susceptibility of Gram-negative bacilli obtain from intraabdominal infections with special focus in isolates with extended spectrum ß-lactamases (ESBLs). MATERIAL AND

METHODS:

The antimicrobial susceptibility of 8,869 isolates was analyzed by microdilution during the SMART study performed in Spain from 2002 to 2010. Isolates were recovered in 16 centres.

RESULTS:

Escherichia coli was the most prevalent pathogen (60.9% from intraabdominal infections acquired in the community and 49.9% in those from nosocomial origin) followed by Klebsiella pneumoniae (8.9% vs 9.2%). Pseudomonas aeruginosa was more common in intraabdominal infections from nosocomial origin (5.6% community and 8.6% nosocomial). Frequency of ESBL-producing isolates was E. coli, 8.7%; K. pneumoniae, 8.4%; Klebsiella oxytoca, 1.4%; and Proteus mirabilis, 1.6%. Overall, ESBL-producing isolates were more frequently isolated from elderly patients (6.8% >60 years). Ertapenem and meropenem were the most active antimicrobials (susceptibility range with EUCAST criteria, 89.0-100%) when considering all Enterobacteriaceae isolates and also against ESBL producers (95.5-100%). Susceptibility of amoxicillin/clavulanic acid and piperacillin/tazobactam was lower, particularly among ESBL-producing isolates. Nevertheless, ertapenem maintained a good activity (susceptibility >95%) in ESBL-producers that were resistant to amoxicillin/clavulanic acid, piperacillin/tazobactam or fluoroquinolones.

CONCLUSIONS:

Antimicrobial susceptibility data from the SMART-Spain study reinforce current therapeutic guidelines of intraabdominal infections that include ertapenem as the empirical choice for treatment. This is also supported by the high frequency of ESBL-producers in our geographic area.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Beta-Lactamases / Infecções por Bactérias Gram-Negativas / Abdome / Bactérias Gram-Negativas Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2011 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Beta-Lactamases / Infecções por Bactérias Gram-Negativas / Abdome / Bactérias Gram-Negativas Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2011 Tipo de documento: Article